Literature DB >> 7913761

Nucleic acids in prion preparations: unspecific background or essential component?

K Kellings1, S B Prusiner, D Riesner.   

Abstract

As recently published (Kellings et al. J. gen Vir. 73, 1025-1029 (1992)), the analysis of purified scrapie prions by return refocusing gel electrophoresis revealed remaining nucleic acids in the size range up to 1100 nucleotides. The results defined the possible characteristics of a hypothetical scrapie-specific nucleic acid. If homogeneous in size, such a molecule would be less than 80 nucleotides in length at a particle-to-infectivity ratio (P:I) near unity; if heterogeneous, scrapie-specific nucleic acids would have to include molecules smaller than 240 nucleotides. To decrease the amount of nucleic acids, several modifications of the PrPSc purification scheme were introduced. Instead of sucrose gradient, ultrafiltration was applied as a purification step and nucleic acids were degraded by Benzonase after ultrafiltration, but significant reduction of the P:I ratio could not be achieved. To prevent trapping of nucleic acids in prion rods, nuclease (Benzonase) was added into the tissue homogenate and incubated at 37 degrees C, overnight. The Benzonase treatment revealed no loss of infectivity, but the whole procedure of nucleic acid analysis did not lead to a reduction of the P:I ratio. In another approach the number of nucleic acid degradations steps was reduced to essentially two steps: Zn2+ hydrolysis and Benzonase digestion. Higher Zn2+ concentrations and prolonged incubation times resulted in a more efficient nucleic acid degradation. The bioassays yielded complete recovery of infectivity. Large-scale preparations for determining the P:I ratio are still underway.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7913761     DOI: 10.1098/rstb.1994.0039

Source DB:  PubMed          Journal:  Philos Trans R Soc Lond B Biol Sci        ISSN: 0962-8436            Impact factor:   6.237


  8 in total

1.  Cell-free propagation of prion strains.

Authors:  Joaquín Castilla; Rodrigo Morales; Paula Saá; Marcelo Barria; Pierluigi Gambetti; Claudio Soto
Journal:  EMBO J       Date:  2008-09-18       Impact factor: 11.598

2.  Abbreviated incubation times for human prions in mice expressing a chimeric mouse-human prion protein transgene.

Authors:  Carsten Korth; Kiyotoshi Kaneko; Darlene Groth; Norbert Heye; Glenn Telling; James Mastrianni; Piero Parchi; Pierluigi Gambetti; Robert Will; James Ironside; Cornelia Heinrich; Patrick Tremblay; Stephen J DeArmond; Stanley B Prusiner
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-08       Impact factor: 11.205

Review 3.  Prion diseases.

Authors:  Edward McKintosh; Sarah J Tabrizi; John Collinge
Journal:  J Neurovirol       Date:  2003-04       Impact factor: 2.643

4.  Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease.

Authors:  C Korth; B C May; F E Cohen; S B Prusiner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

5.  Predicted consequences of site-directed mutagenesis and the impact of species variation on prion protein misfolding through the N-terminal domain.

Authors:  David P Molloy; Beining Chen
Journal:  J Mol Model       Date:  2005-07-21       Impact factor: 1.810

Review 6.  Prions.

Authors:  S B Prusiner
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

Review 7.  Populations of Tau Conformers Drive Prion-like Strain Effects in Alzheimer's Disease and Related Dementias.

Authors:  Lenka Hromadkova; Mohammad Khursheed Siddiqi; He Liu; Jiri G Safar
Journal:  Cells       Date:  2022-09-26       Impact factor: 7.666

Review 8.  Prion protein misfolding.

Authors:  L Kupfer; W Hinrichs; M H Groschup
Journal:  Curr Mol Med       Date:  2009-09       Impact factor: 2.222

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.